Anal Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Anal Cancer – Pipeline Review, H1 2017’, provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Anal Cancer

– The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Anal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Anal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advaxis Inc

Amgen Inc

Atara Biotherapeutics Inc

Bayer AG

BeiGene Ltd

Cell Medica Ltd

Eli Lilly and Company

Immunovaccine Inc

ISA Pharmaceuticals BV

Merck & Co Inc

Millennium Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Oryx GmbH & Co KG

PDS Biotechnology Corp

Sun Pharma Advanced Research Company Ltd

Taiwan Liposome Company Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Anal Cancer Overview 6

Anal Cancer Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 10

Anal Cancer Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Anal Cancer Companies Involved in Therapeutics Development 19

Advaxis Inc 19

Amgen Inc 19

Atara Biotherapeutics Inc 20

Bayer AG 20

BeiGene Ltd 21

Cell Medica Ltd 21

Eli Lilly and Company 22

Immunovaccine Inc 22

ISA Pharmaceuticals BV 23

Merck & Co Inc 23

Millennium Pharmaceuticals Inc 24

Ono Pharmaceutical Co Ltd 24

Oryx GmbH & Co KG 25

PDS Biotechnology Corp 25

Sun Pharma Advanced Research Company Ltd 26

Taiwan Liposome Company Ltd 26

Anal Cancer Drug Profiles 27

alisertib Drug Profile 27

ATA-368 Drug Profile 33

axalimogene filolisbac Drug Profile 34

BAY-1125976 Drug Profile 52

BGBA-317 Drug Profile 53

cisplatin Drug Profile 55

CMD-004 Drug Profile 56

CUE-101 Drug Profile 57

CUE-201 Drug Profile 58

DPXE-7 Drug Profile 59

ISA-101 Drug Profile 60

nivolumab Drug Profile 64

paclitaxel albumin free Drug Profile 104

panitumumab Drug Profile 105

PDS-0101 Drug Profile 111

pembrolizumab Drug Profile 113

prexasertib Drug Profile 161

TLC-388 Drug Profile 163

Vicoryx Drug Profile 165

Anal Cancer Dormant Projects 166

Anal Cancer Discontinued Products 167

Anal Cancer Product Development Milestones 168

Featured News & Press Releases 168

Appendix 180

Methodology 180

Coverage 180

Secondary Research 180

Primary Research 180

Expert Panel Validation 180

Contact Us 180

Disclaimer 181

List of Tables

List of Tables

Number of Products under Development for Anal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Anal Cancer Pipeline by Advaxis Inc, H1 2017

Anal Cancer Pipeline by Amgen Inc, H1 2017

Anal Cancer Pipeline by Atara Biotherapeutics Inc, H1 2017

Anal Cancer Pipeline by Bayer AG, H1 2017

Anal Cancer Pipeline by BeiGene Ltd, H1 2017

Anal Cancer Pipeline by Cell Medica Ltd, H1 2017

Anal Cancer Pipeline by Eli Lilly and Company, H1 2017

Anal Cancer Pipeline by Immunovaccine Inc, H1 2017

Anal Cancer Pipeline by ISA Pharmaceuticals BV, H1 2017

Anal Cancer Pipeline by Merck & Co Inc, H1 2017

Anal Cancer Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Anal Cancer Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Anal Cancer Pipeline by Oryx GmbH & Co KG, H1 2017

Anal Cancer Pipeline by PDS Biotechnology Corp, H1 2017

Anal Cancer Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Anal Cancer Pipeline by Taiwan Liposome Company Ltd, H1 2017

Anal Cancer Dormant Projects, H1 2017

Anal Cancer Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Anal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports